FNDC3B and breast carcinoma: In line with these results, western blot analysis indicated that while FNDC3B overexpression was observed in all GBM cell lines (U87-IDH mutant, U87MG, U251, T98G), its expression was relatively low in cell lines from prostate cancer (PC3) and breast cancer (MCF7) (Figure 2a).